Systematic lymphadenectomy in early stage endometrial cancer
- PMID: 32430757
- DOI: 10.1007/s00404-020-05600-8
Systematic lymphadenectomy in early stage endometrial cancer
Abstract
Background: The positive effect of systematic lymphadenectomy on survival of patients with endometrial cancer is a topic of ongoing debate.
Methods: We aimed to investigate whether systemic lymphadenectomy is beneficial for patients with early endometrial cancer. For this purpose, we analyzed a population-based registry with of 2392 women with endometrioid endometrial cancer, stage I and II at intermediate and high risk of recurrence. The primary outcome measure was overall survival.
Results: After exclusions, 868 women were eligible for analysis. Of those, 511 and 357 were categorized as intermediate (pT1A G3 and pT1B G1-2) and high risk (pT1B G3 and pT2 G1-3) early stage endometrial cancer, respectively. Lymphadenectomy was performed in 527 (60.7%) of the cases. Patients in the lymphadenectomy group were significantly younger, presented with more tumors of intermediate or undifferentiated grade and exhibited significantly lower co-morbidity rates and Eastern Cooperative of Oncology Group (ECOG) performance status. Median follow-up was 6.7 years. Recurrence-free survival was not improved by lymphadenectomy in the intermediate and high-risk group of patients. During the follow-up period, 111 (12.8%) women had disease recurrence and 302 (34.8%) died. Systematic lymphadenectomy was associated with significant improvement of overall survival in the pT1A G3 and pT1B G3 patient subgroups. Notably, adjustment for patient age and ECOG status abolished the improvement of overall survival by systematic lymphadenectomy in all groups. Thus, lymphadenectomy did not improve recurrence-free survival in the intermediate risk or the high-risk group of patients CONCLUSIONS: Systematic pelvic and para-aortic lymphadenectomy did not improve the survival of patients with early stage I and II endometrioid endometrial cancer at intermediate and high risk of recurrence.
Keywords: Endometrial cancer; Lymphadenectomy; Para-aortal; Pelvic.
Similar articles
-
Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP.6).Int J Gynecol Cancer. 2021 Jul;31(7):1075-1079. doi: 10.1136/ijgc-2021-002703. Int J Gynecol Cancer. 2021. PMID: 34226291 Clinical Trial.
-
Combined pelvic and para-aortic is superior to only pelvic lymphadenectomy in intermediate and high-risk endometrial cancer: a systematic review and meta-analysis.Arch Gynecol Obstet. 2020 Jul;302(1):249-263. doi: 10.1007/s00404-020-05587-2. Epub 2020 May 28. Arch Gynecol Obstet. 2020. PMID: 32468162
-
Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis.Lancet. 2010 Apr 3;375(9721):1165-72. doi: 10.1016/S0140-6736(09)62002-X. Epub 2010 Feb 24. Lancet. 2010. PMID: 20188410
-
Does para-aortic lymphadenectomy improve survival in pathologically diagnosed early-stage grade 3 endometrioid and non-endometrioid endometrial cancers? A retrospective cohort study in Korea and Taiwan.Gynecol Oncol. 2022 Oct;167(1):65-72. doi: 10.1016/j.ygyno.2022.08.009. Epub 2022 Aug 20. Gynecol Oncol. 2022. PMID: 35995599
-
Role of complete para-aortic lymphadenectomy in endometrial cancer.Curr Opin Obstet Gynecol. 2009 Feb;21(1):10-4. doi: 10.1097/GCO.0b013e32831ac3ac. Curr Opin Obstet Gynecol. 2009. PMID: 19124998 Review.
Cited by
-
Comprehensive pelvic and paraaortic lymphadenectomy in patients with apparently early stage uterine serous carcinoma - an anachronism?J Gynecol Oncol. 2020 Sep;31(5):e76. doi: 10.3802/jgo.2020.31.e76. J Gynecol Oncol. 2020. PMID: 32808502 Free PMC article. No abstract available.
-
The Evaluation of Sentinel Lymph Node Biopsy Using Radiocolloid in First Stage Endometrial Cancer.Mol Imaging Radionucl Ther. 2023 Jun 20;32(2):103-111. doi: 10.4274/mirt.galenos.2022.36097. Mol Imaging Radionucl Ther. 2023. PMID: 37337763 Free PMC article.
-
Five-year disease-free survival in FIGO IA stage endometrial cancer patients: Tertiary institution experience in a developing country.J Contemp Brachytherapy. 2023 Oct;15(5):297-307. doi: 10.5114/jcb.2023.132191. Epub 2023 Oct 19. J Contemp Brachytherapy. 2023. PMID: 38026070 Free PMC article.
-
Prognostic significance of adjuvant chemotherapy in stage I-II endometrial carcinoma patients who underwent lymphadenectomy.Int J Clin Oncol. 2024 Sep;29(9):1380-1390. doi: 10.1007/s10147-024-02560-w. Epub 2024 Jun 19. Int J Clin Oncol. 2024. PMID: 38896181
-
Therapeutic Benefit of Systematic Lymphadenectomy in Node-Negative Uterine-Confined Endometrioid Endometrial Carcinoma: Omission of Adjuvant Therapy.Cancers (Basel). 2022 Sep 17;14(18):4516. doi: 10.3390/cancers14184516. Cancers (Basel). 2022. PMID: 36139675 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources